Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the University of Oxford are working with clinical collaborators from NHS hospitals to carry out a new clinical drug trial aimed at treating COVID-19, funded by LifeArc. It will test a drug that could raise oxygen levels in the blood in COVID-19 patients in order to improve their chances of recovery. Raising oxygen levels is important in COVID-19, because many patients with the disease die when oxygen levels in their arterial blood fall to levels that are too low to support life.

Currently, supportive therapy for COVID-19 in hospitals aims to keep oxygen levels sufficiently high with treatments such as supplementary oxygen or by using ventilators to artificially support the body’s breathing process. In normal circumstances, if the oxygen becomes too low in a part of the lung, the blood vessels in that part constrict to redirect the blood flow to other regions of the lung where the oxygen is higher. In COVID-19 patients, however, the Oxford University researchers hypothesise that this mechanism is not working properly. Consequently, the blood flow is going to the most diseased and non-functioning parts of the lung where the oxygen is low, and is not getting diverted to the healthier parts of the lung where the oxygen is higher. This means that too much blood flows through the lungs without picking up oxygen.

The Department of Physiology, Anatomy & Genetics (DPAG) led research team aims to address this problem by preferentially constricting the blood vessels going through the diseased parts of the lung, thereby redirecting the blood towards the healthy parts where it can pick up oxygen. To do this, they will use an old drug first developed in France called almitrine bismesylate, which is known in the scientific community to have this effect when treating acute respiratory distress syndrome (ARDS). The drug acts to increase the sensitivity of the acute oxygen sensing mechanisms of the body. According to Lead Researcher Professor Peter Robbins: “We know that almitrine can increase oxygen levels in patients with acute respiratory distress syndrome by constricting the blood vessels in regions of the lung where the oxygen is low. We want to see if almitrine will also have this effect in COVID-19 patients.”

Read the full story on the DPAG website

This story is also featured on the University of Oxford website